News

Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the GCC and Egypt

Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the GCC and Egypt

AD Ports Logistics, subsidiary of AD Ports Group’s Logistics Cluster, chosen as the Exclusive Distributor for UAE, Qatar, Bahrain, Oman, Kuwait and Egypt

Product distribution agreement opens access to Celularity’s Halal-Certified regenerative medicines, health and wellness products across the Middle East

News follows the previously-announced Product Distribution Agreement for the Kingdom of Saudi Arabia 

Abu Dhabi – Gulf Tech News

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogenic cell therapies and biomaterial products announces that it has entered into an exclusive distribution agreement with AD Ports Logistics (ADPL), a subsidiary of the Logistics Cluster, AD Ports Group, the leading global facilitator of trade, logistics and industry based in Abu Dhabi (ADPORTS:ADX). In partnership with CH Trading Group LLC (“CH Trading Group”), an international import, export and trading company and the exclusive territories distributor of Celularity’s previously-announced Halal-Certified regenerative medicine products within more than 100 countries, ADPL will distribute the Celularity’s biomaterial products in the United Arab Emirates, Qatar, Bahrain, Oman, Kuwait and Egypt.

According to the most recent analysis by Emergent Research, the worldwide regenerative medicine market was US $9.80 billion in 2021 and is anticipated to grow at a revenue CAGR of 15.9% to reach US $37.10 billion in 2030.

Farook Al Zeer, Chairman, Logistics Cluster, AD Ports Group, said: “We are pleased to work with Celularity to expand access to these innovative products within the UAE and the region by leveraging our advanced GDP-certified pharma logistics network and the unique capabilities of our Healthcare & Life Sciences Team. Becoming the distributor of choice for Celularity’s biomaterial products is yet another example of how we are working with our industry partners to ensure that our communities across the nation can receive access to the best and most innovative healthcare products possible. We believe that collaborative partnerships such as these will play a significant role in helping deliver on our leadership’s vision of establishing Abu Dhabi as a hub for global healthcare and life science excellence.”

“Today’s announcement highlights a significant milestone in our global expansion strategy and focus on the Middle East and North Africa market,” said Celularity’s CEO, Chairman and Founder, Robert J. Hariri, M.D., Ph.D. “We are proud to partner with AD Ports Logistics to bring our innovative, Halal-Certified biomaterial products into the United Arab Emirates, Qatar, Bahrain, Oman, Kuwait and Egypt.”

“In consultation with our distributors, we look forward to extending the reach of Celularity’s commercial biomaterial products to more people in the Middle East over the next decade,” said CH Trading Group CEO, Sayed Zayan. “We are excited to partner with Celularity and AD Ports Group on increasing access to innovative health and wellness solutions for patients in the GCC region and beyond – and the expanding market for Celularity’s Halal-Certified biomaterial products.”

The Celularity commercial biomaterial products include:

  • Biovance®, a decellularized, dehydrated human amniotic membrane derived from the placenta of a healthy, full-term pregnancy. Biovance® is an intact, extracellular matrix structure that provides a natural scaffold to support the body’s wound healing process.
  • Biovance 3L and Biovance 3L Ocular, tri-layer human amniotic membrane products focused on the surgical and ocular markets and available in both sheet and disk form.
  • Interfyl®, a human connective tissue matrix derived from the placenta of a healthy, full-term pregnancy. It is used by a variety of medical specialists to replace or supplement damaged or inadequate integumental tissue resulting from wounds, trauma, or surgery.
  • CentaFlex™, a decellularized human placental matrix derived from the umbilical cord that can be used as a surgical covering, wrap or barrier to protect and support the repair of damaged tissue.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button